Cencora, Inc. (NYSE:COR) Shares Sold by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC lowered its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 1.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 92,728 shares of the company's stock after selling 1,508 shares during the period. Chevy Chase Trust Holdings LLC's holdings in Cencora were worth $20,834,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of COR. Concord Wealth Partners bought a new stake in shares of Cencora during the third quarter valued at approximately $30,000. Householder Group Estate & Retirement Specialist LLC increased its position in Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after purchasing an additional 69 shares during the last quarter. Kentucky Trust Co bought a new stake in Cencora in the fourth quarter worth $33,000. Ashton Thomas Securities LLC bought a new stake in Cencora in the third quarter worth $41,000. Finally, Modus Advisors LLC bought a new stake in Cencora in the fourth quarter worth $54,000. Institutional investors own 97.52% of the company's stock.

Cencora Stock Up 1.6 %

COR traded up $3.93 on Wednesday, hitting $245.37. The company had a trading volume of 1,553,062 shares, compared to its average volume of 1,509,604. The stock has a market capitalization of $47.58 billion, a price-to-earnings ratio of 34.90, a P/E/G ratio of 1.30 and a beta of 0.49. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The stock has a fifty day moving average price of $238.75 and a 200-day moving average price of $237.41. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $262.26.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. The ex-dividend date is Friday, February 14th. Cencora's payout ratio is currently 31.29%.

Insiders Place Their Bets

In related news, Chairman Steven H. Collis sold 50,000 shares of the company's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the sale, the chairman now owns 326,557 shares in the company, valued at $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. 10.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on COR. Robert W. Baird boosted their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Wells Fargo & Company boosted their price objective on shares of Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a research report on Wednesday, January 29th. Mizuho initiated coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price objective on the stock. Finally, Evercore ISI boosted their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $277.90.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.